ATE502302T1 - Verfahren zum nachweis oder zur überwachung einer bösartigen plasmazellkrankheit - Google Patents

Verfahren zum nachweis oder zur überwachung einer bösartigen plasmazellkrankheit

Info

Publication number
ATE502302T1
ATE502302T1 AT06703629T AT06703629T ATE502302T1 AT E502302 T1 ATE502302 T1 AT E502302T1 AT 06703629 T AT06703629 T AT 06703629T AT 06703629 T AT06703629 T AT 06703629T AT E502302 T1 ATE502302 T1 AT E502302T1
Authority
AT
Austria
Prior art keywords
detecting
immunoglobulins
bound
plasma cell
cell disease
Prior art date
Application number
AT06703629T
Other languages
German (de)
English (en)
Inventor
Arthur Randell Bradwell
Original Assignee
Binding Site Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Binding Site Group Ltd filed Critical Binding Site Group Ltd
Application granted granted Critical
Publication of ATE502302T1 publication Critical patent/ATE502302T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G01N33/57505—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06703629T 2005-01-27 2006-01-26 Verfahren zum nachweis oder zur überwachung einer bösartigen plasmazellkrankheit ATE502302T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501741.3A GB0501741D0 (en) 2005-01-27 2005-01-27 Antibody
PCT/GB2006/000267 WO2006079816A1 (en) 2005-01-27 2006-01-26 Method of detecting or monitoring a malignant plasma cell disease

Publications (1)

Publication Number Publication Date
ATE502302T1 true ATE502302T1 (de) 2011-04-15

Family

ID=34259791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06703629T ATE502302T1 (de) 2005-01-27 2006-01-26 Verfahren zum nachweis oder zur überwachung einer bösartigen plasmazellkrankheit

Country Status (11)

Country Link
US (3) US7897353B2 (cg-RX-API-DMAC7.html)
EP (2) EP2306202B1 (cg-RX-API-DMAC7.html)
JP (3) JP5431674B2 (cg-RX-API-DMAC7.html)
AT (1) ATE502302T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006020688D1 (cg-RX-API-DMAC7.html)
DK (1) DK2306202T3 (cg-RX-API-DMAC7.html)
ES (2) ES2365626T7 (cg-RX-API-DMAC7.html)
GB (1) GB0501741D0 (cg-RX-API-DMAC7.html)
PL (1) PL2306202T3 (cg-RX-API-DMAC7.html)
PT (1) PT2306202E (cg-RX-API-DMAC7.html)
WO (1) WO2006079816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608444D0 (en) 2006-04-27 2006-06-07 Binding Site The Ltd Dialysis
GB0801609D0 (en) * 2008-01-29 2008-03-05 Binding Site The Ltd Hevylite diagnostic stain
EP2414399A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5 antibodies and immunoconjugates and methods of use
GB0914535D0 (en) * 2009-08-19 2009-09-30 Binding Site Group The Ltd Prognosis assay
GB201001950D0 (en) * 2010-02-05 2010-03-24 Binding Site Group The Ltd Infection prognostic assay
GB201001946D0 (en) * 2010-02-05 2010-03-24 Binding Site Group The Ltd Cancer prognostic assay
GB201012049D0 (en) 2010-07-19 2010-09-01 Binding Site Group The Ltd Competition assay
GB201203938D0 (en) 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
US9550004B2 (en) 2013-09-06 2017-01-24 Sensor Electronic Technology, Inc. Ultraviolet diffusive illumination
AU2015240454B2 (en) 2014-04-04 2019-08-22 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
GB201511364D0 (en) * 2015-06-29 2015-08-12 Binding Site Group The Ltd Method of detecting or monitoring an IgG4-related disease
GB2541027A (en) * 2015-08-07 2017-02-08 The Binding Site Group Ltd Treatment
WO2019055634A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF A MACROPHAGE APOPTOSIS INHIBITOR
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
WO2021202992A2 (en) * 2020-04-03 2021-10-07 Lawrence Loomis Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907502A (en) * 1973-12-11 1975-09-23 Miless L Brink Method for identifying Bence Jones proteins
JPS57501147A (cg-RX-API-DMAC7.html) 1980-07-16 1982-07-01
JPS63139199A (ja) * 1986-12-01 1988-06-10 Wakunaga Pharmaceut Co Ltd 抗ヒトＩｇＥモノクロ−ナル抗体及びその用途
ES2184734T3 (es) 1987-04-27 2003-04-16 Inverness Medical Switzerland Dispositivo de prueba analitica para realizar ensayos de union especifica.
US4983530A (en) * 1988-01-29 1991-01-08 E. I. Du Pont De Nemours And Company Sandwich immunoassay for determination of total monoclonal IGG
US5185066A (en) 1988-08-11 1993-02-09 Helena Laboratories Corporation Immunofixation electrophoresis control system
JPH03199966A (ja) * 1989-12-27 1991-08-30 Kazutomo Wakasugi 遊離型ｌ鎖の測定方法
JPH04262792A (ja) * 1990-01-12 1992-09-18 Takeda Chem Ind Ltd 蛋白質の精製法
US5228960A (en) * 1992-07-17 1993-07-20 Beckman Instruments, Inc. Analysis of samples by capillary electrophoretic immunosubtraction
US5552277A (en) * 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
WO1997017372A1 (en) 1995-11-03 1997-05-15 The Binding Site Limited Production of antibodies, and medical uses involving antibodies
GB9718911D0 (en) * 1997-09-05 1997-11-12 Orion Yhtymae Oy Monoclonal antibodies
CA2349290A1 (en) * 1998-11-19 2000-06-02 Elan Corporation, Plc Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
IL157165A0 (en) * 2001-02-20 2004-02-08 Genset Sa Pg-3 and biallelic markers thereof
US20020182748A1 (en) 2001-03-30 2002-12-05 Reardon Paul C. Method and device for testing for Bence-Jones Protein
JPWO2003046009A1 (ja) * 2001-11-27 2005-04-07 持田製薬株式会社 抗ＩＬ１３レセプターα１中和抗体
US20040018576A1 (en) * 2002-07-24 2004-01-29 Dematteo Todd M. Bence Jones protein testing cassette
EP2343315A3 (en) * 2003-02-10 2011-11-23 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US7662387B2 (en) * 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP4473257B2 (ja) * 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
WO2005062044A1 (ja) * 2003-11-19 2005-07-07 Yamasa Corporation ベンスジョーンズ蛋白質の検定法
JP4438455B2 (ja) * 2004-03-04 2010-03-24 ヤマサ醤油株式会社 遊離ヒトイムノグロブリン軽鎖の測定法及びキット
WO2005116651A2 (en) * 2004-05-24 2005-12-08 Diasys Corporation Method and device for testing for bence-jones protein

Also Published As

Publication number Publication date
US8592561B2 (en) 2013-11-26
JP2008528995A (ja) 2008-07-31
JP2013147499A (ja) 2013-08-01
EP1842071B1 (en) 2011-03-16
DK2306202T3 (da) 2014-02-10
US20110177977A1 (en) 2011-07-21
EP1842071A1 (en) 2007-10-10
PL2306202T3 (pl) 2014-05-30
DE602006020688D1 (de) 2011-04-28
JP5715671B2 (ja) 2015-05-13
US20080166742A1 (en) 2008-07-10
ES2455440T3 (es) 2014-04-15
US8415110B2 (en) 2013-04-09
EP1842071B3 (en) 2014-02-26
JP2014025950A (ja) 2014-02-06
GB0501741D0 (en) 2005-03-02
JP6007134B2 (ja) 2016-10-12
ES2365626T7 (es) 2014-06-04
ES2365626T3 (es) 2011-10-07
US7897353B2 (en) 2011-03-01
WO2006079816A1 (en) 2006-08-03
EP2306202B1 (en) 2013-12-18
JP5431674B2 (ja) 2014-03-05
EP2306202A1 (en) 2011-04-06
PT2306202E (pt) 2014-02-27
US20110177535A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
ATE502302T1 (de) Verfahren zum nachweis oder zur überwachung einer bösartigen plasmazellkrankheit
DE60136034D1 (de) Molekular-Modifikations-Assays
ATE449337T1 (de) Assay
DE50204883D1 (de) Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
WO2010049672A3 (en) Methods and products for measuring free immunoglobulin light chain molecules
DE60334029D1 (de) Hochempfindliche assays für die pathogendetektion unterverwendung der metallverstärkten fluoreszenz
WO2011056185A3 (en) Reactivity-dependent and interaction-dependent pcr
WO2009058902A3 (en) Methods and devices for analyte detection
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
WO2007035633A3 (en) Screening assays and methods
ATE532830T1 (de) Langwellige thiolgruppenreaktive fluorophore
ATE522546T1 (de) Verfahren zum nachweis von probnp mit einem monoklonalen antikörper, der die amino saüre 38- 43 bindet
WO2008118558A3 (en) Improved antibody profiling sensitivity through increased reporter antibody layering
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
ATE522811T1 (de) Reagentien, kits und verfahren zum nachweis biologischer moleküle mittels energieübertragung von einem aktivierten chemilumineszenzsubstrat auf einen energieakzeptor-farbstoff
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
WO2010006201A3 (en) Methods of reducing non-specific interaction in metal nanoparticle assays
DE602007010278D1 (de) Proteinnachweisreagentien und -verfahren mit farbstoffen und dextrinen
WO2009075773A3 (en) Identification of toxin ligands
ATE519112T1 (de) Verfahren zum nachweis spezifischer antikörper der immunglobulinklasse g
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
ATE511650T1 (de) Verfahren zum nachweis von antikörpern einer bestimmten klasse über einen immunkomplex spezifischen antikörper
ATE513215T1 (de) Monoklonale antikörper, hybridomzellinien, verfahren und kits zum nachweis von phytase
DE60323105D1 (de) Verfahren zur beseitigung von störungen in immunochromatographischen assays

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties